BioCentury
ARTICLE | Company News

Penn emerges from Novartis alliance a prolific source of cell, gene therapies

September 17, 2019 8:05 PM UTC

University of Pennsylvania is closing out its seven year landmark CAR T partnership with Novartis with a stable of collaborations and a list of new directions for CARs, both in and out of cancer.

Penn’s 2012 deal with Novartis AG (NYSE:NVS; SIX:NOVN) led to the first approved chimeric antigen receptor (CAR) T cell therapy for cancer Kymriah tisagenlecleucel in 2017, now marketed for pediatric relapsed or refractory ALL and relapsed or refractory diffuse large B cell lymphoma (DLBCL)...